Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1/2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa

Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1/2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa

– DSP-3077 is an investigational allogeneic iPS cell-derived retinal sheet (3-dimensional [3D] retina) that is administered via subretinal injection –

– The Phase 1/2a study is evaluating safety and tolerability of DSP-3077 as well as engraftment and potential therapeutic response at two dose levels –

– Retinitis pigmentosa (RP) is a group of genetic eye disorders characterized by the progressive degeneration of photoreceptor cells in the retina, leading to vision loss1 –

Sumitomo Pharma America, Inc. (SMPA) today announced that the first patient in its study evaluating DSP-3077 in the treatment of non-syndromic retinitis pigmentosa (RP) has undergone subretinal implantation. DSP-3077 is an investigative regenerative cell therapy that leverages allogeneic retinal sheets derived from induced pluripotent stem (iPS) cells.